What the Clinical Trial Data Shows About Patient Selection Getting GLP-1 prescribing right requires matching the right patient to the right drug
The Wegovy pill isnt FDA-approved for diabetes, although clinical trials do show reduction in blood sugar for those with prediabetes over the course of 64 weeks
Our DART-Seq data also provide insight into the importance of islet endocrine cell heterogeneity under basal conditions and GLP-1Rstimulated conditions
Unfortunately, this is the potential scenario of peptide marketing and use in such an unregulated environment
By synthesizing existing evidence, this review highlights the promising role of tirzepatide in redefining the therapeutic landscape of T2D, providing valuable information for future research and clinical applications
Consistency with rotation Whichever site you choose, it should be part of a structured rotation plan (discussed further below) to prevent tissue damage over time